Onconetix, Inc. Stock

ONCO

US68237Q4010

Pharmaceuticals

End-of-day quote Nasdaq 27/10/2026			5-day change	1st Jan Change
0.4746 ^USD	+18.92%		+9.05%	-99.39%

08/10	RBC Raises Price Target on Onconetix to $459 From $450, Keeps Outperform Rating	MT
25/09	SRX Global Inc. acquired an unknown minority stake in Onconetix, Inc..	CI

Last Transcript: Onconetix, Inc.

Onconetix, Inc., Realbotix Corp. - M&A Call

14/02

More transcripts

Analysts' recommendations: Onconetix, Inc.

08/10	RBC Raises Price Target on Onconetix to $459 From $450, Keeps Outperform Rating	MT
14/09/23	Maxim Downgrades Blue Water Biotech to Hold From Buy	MT
27/04/23	HC Wainwright Adjusts Price Target on Blue Water Biotech to $9 From $7, Maintains Buy Rating	MT
09/12/22	Maxim Starts Blue Water Vaccines at Buy With $4 Price Target	MT

More recommendations

Press Releases: Onconetix, Inc.

25/09	SRX Global Provides Shareholders with Update on Liquidation of Two Portfolio Investments and Adds an Investment in Onconetix (Nasdaq: ONCO)	AQ
14/09	Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition	AQ
03/09	Onconetix Acquisition Target Realbotix Launches Pilot with Leading European Telecommunications Company to Deploy Humanoid Robots in Live Presentations and Events	AQ
06/08	Onconetix Acquisition Target Realbotix Secures Agreement for Humanoid Robot Appearance on Emmy Award-Winning Streaming Series	AQ
05/08	Onconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AG	AQ

More press releases

News in other languages: Onconetix, Inc.

04/04/22

++ Analysen des Tages von Dow Jones Newswires (04.04.2022) +++

More news

Managers and Directors: Onconetix, Inc.

Manager	Title	Age	Since
David White CEO	Chief Executive Officer	73	18/03/2026
Karina Fedasz CEO	Chief Executive Officer	53	02/04/2025

Director	Title	Age	Since
Sarah Romano BRD	Director/Board Member	46	05/12/2025
Sammy Dorf CHM	Chairman	41	23/04/2026
Joshua Epstein BRD	Director/Board Member	47	23/04/2026

More insiders

Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for menâ€™s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patientâ€™s regular Prostate-Specific Antigen (PSA) test.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
28/10/26	USD 0.5979	+25.98%	45,224,682
27/10/26	USD 0.4746	+18.92%	2,515,473
26/10/26	USD 0.3991	-4.52%	829,935
23/10/26	USD 0.4180	+2.75%	572,991
22/10/26	USD 0.4068	-6.53%	554,721

End-of-day quote Nasdaq

More quotes

Market Cap	2.36M 2.12M 1.96M 1.77M 3.31M 225M 3.35M 23.42M 9.33M 118M 8.86M 8.67M 374M	P/E 2024 *	-	P/E 2025	-0.09x
Enterprise Value	-2.81M -2.52M -2.33M -2.11M -3.94M -268M -3.99M -27.88M -11.1M -140M -10.55M -10.32M -445M	EV / Sales 2024	5,556,319x	EV / Sales 2025	-3,367,890x
Free-Float	88.93%	Yield 2024 *	-	Yield 2025	-

08/10	RBC Raises Price Target on Onconetix to $459 From $450, Keeps Outperform Rating	MT
25/09	SRX Global Inc. acquired an unknown minority stake in Onconetix, Inc..	CI
25/09	SRX Global Makes Investment in Onconetix	MT
01/09	White House Cuts Deal to Lower Prescription Drug Prices With Nine Companies	MT
14/08	Onconetix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
28/07	Onconetix, Inc. announced that it expects to receive $780.2496 million in funding	CI
19/05	Onconetix, Inc. announces 1-for-10 reverse stock split	RE
19/05	Realbotix provides update on Nasdaq listing	RE
13/05	Onconetix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
25/04	Onconetix Inc Andrew Oakley resigns as chairman of board	RE
25/04	Onconetix, Inc. Announces Board and Committee Changes	CI
01/04	Onconetix appoints David White as chief executive officer and Sammy Dorf as member of the board of directors	RE
25/03	Onconetix on March 18 appointed David White as CEO, effective as of that date	RE

1 day	+18.92%
1 week	+9.05%
Current month	-39.33%
1 month	-57.24%
3 months	-42.83%
6 months	-93.82%
Current year	-99.39%

1 week	0.34	0.68
1 month	0.34	0.87
Current year	0.34	115
1 year	0.34	200
3 years	0.34	90,949.27
5 years	0.34	15,452,876.38
10 years	0.34	15,452,876.38

Date	Insider	Type	Main position	Quantity	% Market Cap.
14/4/26	HRT Financial LP	Sell	Company	49,710	7.1739%
14/4/26	HRT Financial LP	Other	Company	104,498	15.0807%
14/4/26	HRT Financial LP	Sell	Company	182,965	26.4047%

Onconetix, Inc. Stock

Stocks

ONCO

US68237Q4010

Pharmaceuticals

Valuation: Onconetix, Inc.

Chart: Onconetix, Inc.

Latest news: Onconetix, Inc.

Last Transcript: Onconetix, Inc.

Analysts' recommendations: Onconetix, Inc.

Press Releases: Onconetix, Inc.

News in other languages: Onconetix, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Onconetix, Inc.

Latest insider transactions

Biopharmaceuticals

Financials

Company Profile

Quotes

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ONCONETIX, INC.	+18.92%	+9.05%	-99.73%	-100.00%	2.36M
ELI LILLY AND COMPANY	+0.50%	+1.38%	+57.09%	+129.96%	1,148B
JOHNSON & JOHNSON	+0.86%	+5.14%	+45.00%	+86.15%	652B
ABBVIE INC.	-0.14%	+0.42%	+25.69%	+105.85%	505B
ROCHE HOLDING AG	+0.39%	+2.24%	+53.96%	+66.14%	384B
MERCK & CO., INC.	-0.63%	-5.97%	+61.93%	+37.06%	348B
NOVARTIS AG	+2.11%	+2.42%	+34.01%	+55.97%	294B
ASTRAZENECA PLC	+0.91%	-0.66%	+2.66%	+26.19%	264B
AMGEN INC.	+0.87%	+3.08%	+54.69%	+72.74%	244B
GILEAD SCIENCES, INC.	+0.08%	+3.67%	+35.05%	+107.78%	197B
Average	+2.39%	+2.15%	+27.03%	+58.79%	403.72B
Weighted average by Cap.	+0.51%	+1.50%	+44.87%	+89.08%

	2024	2025
Net sales	2.52 2.26 2.09 1.9 3.54 240.4 3.59 25.03 9.97 125.8 9.47 9.27 399.36	0.82 0.73 0.68 0.61 1.14 77.66 1.16 8.09 3.22 40.64 3.06 3 129
Net income	-58.69M -52.66M -48.68M -44.09M -82.37M -5.59B -83.37M -582M -232M -2.93B -220M -216M -9.29B	-14.03M -12.59M -11.64M -10.54M -19.69M -1.34B -19.93M -139M -55.43M -699M -52.66M -51.55M -2.22B
Net Debt	8.8M 7.9M 7.3M 6.61M 12.35M 838M 12.5M 87.29M 34.77M 439M 33.03M 32.33M 1.39B	-5.17M -4.64M -4.29M -3.89M -7.26M -493M -7.35M -51.29M -20.43M -258M -19.41M -19M -818M